Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-08-06 01:28 | 2025-08-01 | ARQT | Arcutis Biotherapeutics Inc. | Welgus Howard G. | Director | OPT+S | $14.30 | 10,000 | $142,982 | 100,206 |
| 2025-08-06 01:28 | 2025-08-04 | ARQT | Arcutis Biotherapeutics Inc. | Burnett Patrick | Officer | SELL | $14.33 | 2,622 | $37,564 | 112,846 |
| 2025-08-06 00:16 | 2025-08-01 | ONC | BeOne Medicines Ltd. | Rosenberg Aaron | Officer | SELL | $290.47 | 1,190 | $345,659 | 0 |
| 2025-08-05 23:05 | 2025-08-01 | STOK | Stoke Therapeutics, Inc. | Ticho Barry | Officer | SELL | $12.82 | 4,504 | $57,724 | 16,775 |
| 2025-08-05 23:07 | 2025-08-01 | AUPH | Aurinia Pharmaceuticals Inc. | Keenan Greg | Officer | SELL | $10.50 | 20,000 | $210,000 | 133,484 |
| 2025-08-06 00:27 | 2025-08-04 | RNA | Avidity Biosciences, Inc. | Moriarty John B | Officer | SELL | $36.21 | 2,245 | $81,291 | 47,755 |
| 2025-08-06 00:58 | 2025-08-02 | BMY | BRISTOL MYERS SQUIBB CO | Short Bartie Wendy | Officer | OPT+S | $44.23 | 378 | $16,719 | 5,066 |
| 2025-08-06 00:03 | 2025-08-01 | LGND | LIGAND PHARMACEUTICALS INC | KOZARICH JOHN W | Director | SELL | $131.88 | 467 | $61,586 | 45,989 |
| 2025-08-05 23:54 | 2025-08-01 | JAZZ | Jazz Pharmaceuticals plc | COZADD BRUCE C | Director, Officer | SELL | $113.21 | 1,000 | $113,210 | 435,973 |
| 2025-08-06 00:31 | 2025-08-01 | AUPH | Aurinia Pharmaceuticals Inc. | TANG KEVIN | Director | BUY | $10.45 | 1,300,000 | $13,589,940 | 11,329,500 |
| 2025-08-06 01:51 | 2025-08-01 | CORT | CORCEPT THERAPEUTICS INC | Maduck Sean | Officer | OPT+S | $67.79 | 35,007 | $2,373,237 | 7,681 |
| 2025-08-06 01:51 | 2025-08-01 | CORT | CORCEPT THERAPEUTICS INC | BELANOFF JOSEPH K | Director, Officer | SELL | $68.53 | 40,000 | $2,741,208 | 2,861,370 |
| 2025-08-06 01:47 | 2025-08-01 | CORT | CORCEPT THERAPEUTICS INC | Lyon Joseph Douglas | Officer | OPT+S | $67.51 | 5,823 | $393,128 | 10,066 |
| 2025-08-06 03:30 | 2025-08-05 | PTCT | PTC THERAPEUTICS, INC. | Klein Matthew B. | Director, Officer | SELL | $51.74 | 10,739 | $555,636 | 337,767 |
| 2025-08-06 01:28 | 2025-08-05 | CYTK | CYTOKINETICS INC | Malik Fady Ibraham | Officer | OPT+S | $36.34 | 2,000 | $72,680 | 140,610 |
| 2025-08-04 16:00 | 2025-07-31 | ANIX | Anixa Biosciences Inc. | Titterton Lewis H jr | Director | BUY | $3.08 | 10,000 | $30,800 | 953,334 |
| 2025-08-05 02:17 | 2025-08-01 | AMPH | Amphastar Pharmaceuticals Inc. | Petersen Floyd F. | Director | SELL | $20.83 | 500 | $10,416 | 77,031 |
| 2025-08-05 02:23 | 2025-07-30 | CYCC | Bio Green Med Solution, Inc. | Lazar David E. | 10% owner | SELL | $12.36 | 6,750 | $83,430 | 155,838 |
| 2025-08-05 01:28 | 2025-07-31 | LRMR | Larimar Therapeutics, Inc. | Flynn James E | Director, 10% owner | BUY | $3.20 | 9,375,000 | $30,000,000 | 7,321,129 |
| 2025-08-01 23:30 | 2025-07-30 | NUVL | Nuvalent, Inc. | Noci Darlene | Officer | OPT+S | $80.36 | 4,000 | $321,440 | 48,034 |
| 2025-08-01 23:32 | 2025-07-30 | IRON | Disc Medicine, Inc. | Bitterman Kevin | Director | SELL | $61.04 | 8,492 | $518,352 | 625,477 |
| 2025-08-02 00:09 | 2025-08-01 | NRIX | Nurix Therapeutics, Inc. | van Houte Hans | Officer | SELL | $11.03 | 5,402 | $59,598 | 35,512 |
| 2025-08-01 23:06 | 2025-07-30 | IONS | IONIS PHARMACEUTICALS INC | Monia Brett P | Director, Officer | OPT+S | $45.00 | 2,432 | $109,440 | 179,820 |
| 2025-08-01 23:30 | 2025-07-30 | ANNX | Annexon, Inc. | Carson William H. | Director | BUY | $2.43 | 4,115 | $9,999 | 33,830 |
| 2025-08-01 23:30 | 2025-07-30 | ALZN | Alzamend Neuro Inc. | AULT MILTON C III | Director, 10% owner | SELL | $2.28 | 129,449 | $295,532 | 8,260 |
| 2025-08-01 00:05 | 2025-07-29 | ONC | BeOne Medicines Ltd. | Wang Lai | Officer | SELL | $302.65 | 4,300 | $1,301,375 | 0 |
| 2025-08-01 00:04 | 2025-07-30 | ONC | BeOne Medicines Ltd. | Lee Chan Henry | Officer | SELL | $304.60 | 920 | $280,233 | 0 |
| 2025-07-31 16:00 | 2025-07-30 | ANIX | Anixa Biosciences Inc. | KUMAR AMIT | Officer | BUY | $3.16 | 5,000 | $15,800 | 579,925 |
| 2025-07-31 23:38 | 2025-07-29 | CYTK | CYTOKINETICS INC | Blum Robert I | Director, Officer | SELL | $36.45 | 5,000 | $182,250 | 388,108 |
| 2025-07-31 00:00 | 2025-07-29 | CNTA | Centessa Pharmaceuticals plc | Accardi Mario Alberto | Officer | SELL | $15.23 | 8,322 | $126,751 | 208,163 |
| 2025-07-30 23:30 | 2025-07-28 | LQDA | Liquidia Corp | Boyle Dana | Officer | SELL | $19.54 | 1,063 | $20,771 | 186,105 |
| 2025-07-30 23:31 | 2025-07-28 | LQDA | Liquidia Corp | Adair Jason | Officer | SELL | $19.54 | 454 | $8,871 | 193,180 |
| 2025-07-31 03:12 | 2025-07-28 | MLYS | Mineralys Therapeutics, Inc. | Levy Adam Scott | Officer | SELL | $14.62 | 73,678 | $1,077,474 | 132,934 |
| 2025-07-31 00:57 | 2025-07-28 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | Officer | OPT+S | $20.46 | 3,250 | $66,504 | 23,000 |
| 2025-07-30 23:03 | 2025-07-28 | URGN | UroGen Pharma Ltd. | Smith Jason Drew | Officer | OPT+S | $19.14 | 7,522 | $143,971 | 41,492 |
| 2025-07-30 23:02 | 2025-07-28 | URGN | UroGen Pharma Ltd. | Schoenberg Mark | Officer | OPT+S | $19.14 | 5,149 | $98,552 | 158,229 |
| 2025-07-31 01:49 | 2025-07-30 | NRIX | Nurix Therapeutics, Inc. | van Houte Hans | Officer | OPT+S | $12.01 | 4,304 | $51,695 | 40,914 |
| 2025-07-31 01:49 | 2025-07-30 | NRIX | Nurix Therapeutics, Inc. | Ring Christine | Officer | OPT+S | $12.01 | 3,841 | $46,134 | 44,009 |
| 2025-07-31 01:48 | 2025-07-30 | NRIX | Nurix Therapeutics, Inc. | Hansen Gwenn | Officer | OPT+S | $12.01 | 4,308 | $51,743 | 69,023 |
| 2025-07-30 23:56 | 2025-07-29 | KPTI | Karyopharm Therapeutics Inc. | Poulton Stuart | Officer | SELL | $4.37 | 191 | $835 | 27,223 |
| 2025-07-30 19:37 | 2025-07-29 | LEXX | Lexaria Bioscience Corp. | McKechnie William Edward | Director | BUY | $0.91 | 5,000 | $4,532 | 18,191 |
| 2025-07-30 18:34 | 2025-07-29 | LEXX | Lexaria Bioscience Corp. | DOCHERTY JOHN MARTIN | Director, Officer | BUY | $0.93 | 5,376 | $4,989 | 5,376 |
| 2025-07-30 18:23 | 2025-07-29 | LEXX | Lexaria Bioscience Corp. | Carle Vanessa | Officer | BUY | $0.91 | 750 | $683 | 750 |
| 2025-07-30 20:47 | 2025-07-29 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Officer | OPT+S | $6.50 | 4,196 | $27,274 | 0 |
| 2025-07-30 18:14 | 2025-07-29 | LEXX | Lexaria Bioscience Corp. | CHRISTOPHER RICHARD | Director, Officer | BUY | $0.91 | 15,000 | $13,641 | 65,000 |
| 2025-07-31 00:12 | 2025-07-29 | LEXX | Lexaria Bioscience Corp. | BUNKA CHRISTOPHER | Director | BUY | $0.92 | 27,500 | $25,242 | 281,912 |
| 2025-07-30 01:56 | 2025-07-29 | RYTM | RHYTHM PHARMACEUTICALS, INC. | Cramer Pamela J. | Officer | OPT+S | $85.93 | 1,520 | $130,614 | 20,814 |
| 2025-07-29 23:52 | 2025-07-28 | CALC | CalciMedica, Inc. | Stauderman Kenneth A. | Officer | BUY | $3.96 | 1,000 | $3,960 | 12,944 |
| 2025-07-29 23:52 | 2025-07-25 | CALC | CalciMedica, Inc. | Stauderman Kenneth A. | Officer | SELL | $3.65 | 1,000 | $3,650 | 0 |
| 2025-07-29 13:10 | 2025-07-28 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Officer | OPT+S | $5.89 | 6,500 | $38,285 | 0 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.